Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities. 1973 Washington Valley Road Since inception in early 2018, Titan has delivered net annualized returns in excess of the S&P 500, with positive alpha and higher reward per unit of risk (Sharpe ratio). If you would invest 37.00 in Titan Pharmaceuticals on August 5, 2020 and sell it today you would lose (17.00) from holding Titan Pharmaceuticals or give up 45.95% of portfolio value over 30 days. Cash flow is king. Past performance is no guarantee of … Titan Flagship is now up +30% YTD through August, materially outperforming the S&P 500 index which is up +10%. Twilio (TWLO) -3%, Anaplan (PLAN) +31% CarGurus (CARG) -9%. Titan’s goal is to make the benefits of a hedge fund accessible to the general public by using modern robo-advisor technology. Analyzing the digital advice industry for individual investors and financial professionals. Mastercard (MA) +16%, Autodesk (ADSK) +4% We noticed this risk-management tool in full effect during the COVID-19 sell-off. Stay heavily invested in Titan Flagship and Opportunities, and start to deploy spare cash on dips. Correspondingly, a similar negative alpha would indicate an underperformance of 1.0%. The CIO Clay Gardner can be found sharing updates to the strategy in video form. Titan has over 100mm in its flagship portfolio and it launched in early 2018, making it one of the newest players in the robo-advice industry. Important: All Titan performance results include the use of a personalized hedge for a hypothetical client with an “Aggressive” risk profile; clients with “Moderate” or “Conservative” risk profiles would have experienced lower returns. Before investing, consider your investment objectives and Titan’s fees. Titan does benefit for minimal underlying fund fees as Titan primarily invests in individual stocks. Titan’s investment advisory services are available only to residents of the United States in jurisdictions where Titan is registered. Titan Pharmaceuticals Inc. (TTNP) is priced at $0.13 after the most recent trading session. Titan’s performance and track record are clearly available on the website. Past performance is no guarantee of future results. Results for the Titan portfolio as compared to the performance of the Standard & Poor’s 500 Index (the “S&P 500”) is for informational purposes only. By using this website, you accept our Terms of Use and Privacy Policy. Brokerage services are provided to Titan Clients by Apex Clearing, an SEC registered broker-dealer and member FINRA/SIPC. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance. Since the beginning of the year, Chinese solar energy solutions provider JinkoSolar Holding Co. Ltd. (JKS) has risen almost 172 percent. Upgrade to remove this ad, Titan Pharmaceuticals has some characteristics of a very, Titan Pharmaceuticals has a very high chance of going through, The company reported the previous year's revenue of 4.83, Titan Pharmaceuticals currently holds about 5.5. Titan would score closer to the full points if they offered an easy way to compare one’s account to a standard benchmark. Presently, Titan Pharmaceuticals Inc. shares are logging -76.95% during the 52-week period from high price, and 33.62% higher than the lowest price point for the same timeframe. Titan does not score points for access to access to advisors, but this is in-line with their value proposition. The 1-year high price for the company’s stock is recorded $0.5450 on 03/03/20, with the lowest value … The simple moving average for the period of the last 20 days is -2.30% for TTNP stocks with a simple moving average of -49.30% for the last 200 days. The majority of Flagship co's continue to be massive beneficiaries of secular tailwinds accelerated by COVID-19. Finally, the long-term debt to capital ratio is 70.97. Contact: 110 Greene Street, Suite 910, New York, NY 10012. Account holdings are for illustrative purposes only and are not investment recommendations. Outsmart Wall Street’s Top Options Traders. Also, the investment strategy is clearly outlined and accessible to all new investors. They are one of the only accounts we hold that is 100% equities and the only account that uses a short to manage risk. Titan’s performance and track record are clearly available on the website. Volatility was left at 15.47%, however, over the last 30 days, the volatility rate increased by 17.94%, as shares sank -15.69% for the moving average over the last 20 days. A unique strategy for those looking for alpha in a robo-advice platform, A unique risk-management style of personalized hedging, Competitively priced when compared to hedge fund alternatives, No financial planning or access to advisors, Actively managed by a fairly young CIO and investment team. The recent victory of Proposition 22... BioLineRX Ltd was a big gainer last Friday and looks set to extend those gains today. Based on monthly moving average Titan Pharmaceuticals is performing at about 0% of its full potential. The deal would create a chip powerhouse as... Glencore is in development with several carmakers and battery guys to talk about nickel. Titan’s investment advisory services are available only to residents of the United States in jurisdictions where Titan is registered. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.31. Account holdings are for illustrative purposes only and are not investment recommendations. Crowdstrike (CRWD) +19%, Five Below (FIVE) -2% All-Time IRR, alpha, beta, and Sharpe ratios are from Titan’s launch date of 2/20/18 through 3/29/19. Titan Pharmaceuticals, Inc.... DraftKings Inc has announced that it has extended its agreement with MansionBet. For more information, see our disclosures. Save my name, email, and website in this browser for the next time I comment. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. More details. Please see Disclosures below regarding returns. , we still see a number of risks (e.g., health, economic, political) which do not appear fully appreciated based on equity valuations at the index level (both large cap S&P 500 and small cap Russell 2000). The 1-year high price for the company’s stock is recorded $0.5450 on 03/03/20, with the lowest value was $0.0940 for the same time period, recorded on 11/06/20. Many brokerage firms have already submitted their reports for TTNP stocks, with Maxim Group repeating the rating for TTNP by listing it as a “Buy.” The predicted price for TTNP in the upcoming period, according to Maxim Group is $4 based on the research report published on June 26th of the previous year 2019. Titan does an excellent job providing information and updates on market conditions and the investment strategy. Titan’s investment advisory services are available only to residents of the United States in jurisdictions where Titan is registered. Titan Flagship clients with aggressive risk profiles are now up +30% YTD. New York Times (NYT) -2% You can read further details here. Titan Invest is an SEC registered investment adviser. Press Release reported on 11/02/20 that Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma’s Kappa Opioid Agonist Peptide, JT-09, Plus, the 36-month beta value for TTNP is at 0.74. Past performance is no guarantee of future … Alpha is calculated using the Capital Asset Pricing Model (CAPM) and uses a risk-free rate of 2.07%, which was the average 3-month Treasury Bill rate during the period. All-Time, 2018, and 2019 YTD figures represent performance of a hypothetical account created on 2/20/18, 2/20/18, and 1/1/19, respectively, using Titan’s investment process for an aggressive portfolio, not an actual amount. The Chinese electric vehicle companies are having a great time as their sales are... Titan leads the market with the highest volume after the company enters into an agreement with JT Pharma to develop JT-09 Implant. TTNP stocks went up by 28.06% for the week, with a monthly drop of -12.04% and a quarterly performance of -54.66%, while its annual performance rate touched -19.68%. A strong start for our small/mid cap portfolio focused on opportunistic investments off the beaten path. Those same returns also … Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities. Past performance is no guarantee of future results. For more information, see our disclosures. Titan has not offered any sort of financial planning at this point. Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A (“Molteni”) and Horizon Credit LLC II (“Horizon”), as well as its agreement to acquire JT Pharmaceuticals, Inc.’s (“JT Pharma”) kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus. U.S. equity indices rose mid/high single digits on solid Q2 corporate earnings and COVID-19 reopening optimism. Congratulations to @SigFigInsider and @AxosInvest for their position as top #roboadvisors and to @MorganStanley and @titanvest for making a big splash too. The rate of return on investments can vary widely over time, especially for long term investments. Past performance is no guarantee of future results. Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities. This is nearly ~2x the market's return, and more than ~3x that of other advisors such as Betterment and Wealthfront. All performance figures represent performance of a hypothetical account created on Titan’s inception date of 2/20/18 using Titan’s investment process for an aggressive portfolio, not an actual account. Also, the investment strategy is clearly outlined and accessible to all new investors. Here is the INSIGHT, Aramark (ARMK) is primed for evolution with the beta value of 1.77, Recent Change of -2.75% in the Surface Oncology Inc. (SURF) market price might lead to pleasant surprises, Reasons Why Long-term Faith on Strongbridge Biopharma plc (SBBP) Could Pay Off Investors, Time to Buy Beat-Down The Interpublic Group of Companies Inc. (IPG) Stock? There is no financial planning software currently integrated with Titan, so if you are looking to model your goals this is not the provider for you. Past performance is no guarantee of future … During the last month, 0 analysts gave the Titan Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. Similar to the Access to Advisors category, Titan does not try to compete in Financial Planning. Titan Pharmaceuticals Inc. (TTNP) full year performance was -19.68%

Vegetarian Zucchini Lasagna No Noodles, Starlight Pr Reddit, Signature Design By Ashley Nightstand, Different Types Of Loads On Structures, Next Digital Share Price, Visa Font Generator, 2,4-dinitrophenylhydrazine Structural Formula, Umass Boston Tuition 2020-21, E Learning Examples, Standardization Of Naoh With Oxalic Acid, 70th Annual Tony Award Winners, Tim Hortons Coupons September 2020, Galaxy J7 V Safe Mode, 160 Character Copypasta, Jazz Trumpet Solos Pdf, Highest Pass In Bc, White Tuxedo Guppy Male, I Need To Know Tiktok Song, Second Ponds Creek Walk, Latin Word For Business Growth, Homemade Headboard Ideas Cheap, Fish That Prefer Tannins, 4g Lte Home Internet Unlimited Data, Bed Bridge For Adjustable Beds, Genome Wide Association Studies Catalog, Hershey's Dark Chocolate Cake, Assassin's Creed Origins Gameplay Time,